Hot Off The Press!

Issa and Chinmay cover the latest acquisitions and licensing deals for Vertex.

Earlier in 2026, Vertex announced their acquisition of Crinetics Pharmaceuticals.

Vertex also entered into licensing agreements with Zai Lab and Ono Pharma in 2025, and with Halozyme Therapeutics in 2026.

What do these deals mean for Vertex? And for the industry? Listen in.

Hot Off The Press!

Rakesh and Chinmay cover AbbVie’s acquisitions and licensing deals in 1st Half of 2026.

Earlier this year, AbbVie bought Apogee Therapeutics.

AbbVie also entered into licensing agreements with Zejing Biopharmaceutical, RemeGen Biosciences, Haisco Pharma Group, and Ichnos Glenmark Innovation.

Tune in to hear about what it all means for AbbVie, and for industry.

Hot Off The Press!

Issa and Chinmay cover Novartis' acquisitions in 1st Half of 2026.

Novartis has picked up Tourmaline Bio, Avidity Biosciences, Pikavation Therapeutics, Excelergy, and Myricx Bio.

Tune in to hear about what it all means for Novartis, and for the industry.

Issa and Chinmay cover Eli Lilly's acquisitions in 1st Half of 2026.

Eli Lilly has spent nearly $32B for 13 companies so far this year. These include Centessa Pharmaceuticals, Kelonia Therapeutics, Ventyx Biosciences, and AtaiBeckley.

Be sure to listen through the end for the addition on Merida Biosciences, and other latest acquisitions.

Hot Off The Press!

Issa and Chinmay cover Merck Group and Merck & Co.'s acquisitions in 1st Half of 2026. Merck's buying spree has included JSR Life Sciences, Bio-Techne, Terns Pharmaceuticals, and Cidara Therapeutics. What do these acquisitions mean for Merck and the industry? Listen in.